Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Oncorus, Inc. - Common Stock (NQ: ONCR )

N/A UNCHANGED
Last Price Updated: 11:52 AM EDT, Jun 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncorus, Inc. - Common Stock

< Previous 1 2 3 4 Next >
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Mid-Afternoon Market Update: Dow Surges 150 Points; Team Shares Drop
Toward the end of trading Friday, the Dow traded up 0.42% to 36,071.48 while the NASDAQ rose 0.84% to 15,835.89. The S&P also rose, gaining 0.61% to 4,677.60. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
Why Did Oncorus Shares Slump To 52-Week Low Today?
Oncorus Inc (NASDAQ: ONCR) shares slumped after the company reported initial data for its investigational cancer therapy ONCR-177 from a Phase 1 trial in heavily pretreated... 
Via Benzinga
Mid-Day Market Update: Everspin Jumps After Q3 Results; Acutus Medical Shares Plummet
Midway through trading Friday, the Dow traded up 0.31% to 36,031.95 while the NASDAQ rose 0.54% to 15,788.64. The S&P also rose, gaining 0.43% to 4,669.15. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
48 Stocks Moving In Friday's Mid-Day Session
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares climbed 41% to $9.28 after the company reported better-than-expected Q3results and issued Q4 sales guidance above... 
Via Benzinga
Why Oncorus Stock Is Crashing Today
The company announced initial data from a phase 1 study. 
Via The Motley Fool
Mid-Morning Market Update: Markets Rise; AstraZeneca's COVID-19 Vaccine Turns Profitable In Third Quarter
Following the market opening Friday, the Dow traded up 0.25% to 36,012.29 while the NASDAQ rose 0.24% to 15,741.23. The S&P also rose, gaining 0.14% to 4,655.99. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures COVID-19 US Equities
Oncorus, Gaeta Therapeutics Ink Cancer Candidate Licensing Agreement
Oncorus Inc (NASDAQ: ONCR) has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd, related to the use of locally delivered Interleukin-12 (IL... 
Via Benzinga
DPS Group Tapped by Oncorus to Design GMP Clinical Manufacturing Facility
Clinical stage biopharmaceutical company focused on viral immunotherapies building out state-of-the-art, 88,000 square foot facility in Massachusetts BOSTON, MA / ACCESSWIRE / September 22, 2021 / DPS... 
From DPS Group - Boston
Via AccessWire
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
78 Biggest Movers From Friday
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.